RCKT Research and Charts

RCKT - Rocket Pharmaceuticals Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2025-02-06 (Delayed quote data 2025-01-06)

Last 12.35	Change ⇓ -0.21 (-1.67%)	Volume 1,158,152
	Open 12.63	High 12.94	Low 12.32

8EMA (Daily) 12.29	40EMA (Daily) 13.48	50EMA (Daily) 13.96	STO (Daily) 49.761	MACD Hist (Daily) 0.397
8EMA (Weekly) 13.080	40EMA (Weekly) 17.85	50EMA (Weekly) 18.53	STO (Weekly) 9.325	MACD Hist (Weekly) -0.469


Company Profile
Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.